Asian Investigation of Lanreotide Autogel® in the Management of GEP-NETs (AIM-NETs)

  • End date
    Jan 30, 2025
  • participants needed
  • sponsor
    Asan Medical Center
Updated on 4 October 2022


Lanreotide Autogel® has been established as a standard of care for patients with locally advanced or metastatic GEP-NETs based on the success of CLARINET trial. However, only few patients with Asian ethnicity were included in the trial.

According to the nationwide comprehensive study of patients with GEP-NET in Korea, hindgut primary NETs(Rectal) occured more frequently than western countries. However, small intestine or lung primary NET is relatively rare compared with western countries.1) Considering the clinical characteristics of GEP-NETs are distinct between the patients in Asian and Western countries, further evaluation on the efficacy and safety of Lanreotide Autogel® in Asian patients with GEP-NETs is needed.

Condition Neuroendocrine Tumors
Treatment Lanreotide Autogel
Clinical Study IdentifierNCT04696042
SponsorAsan Medical Center
Last Modified on4 October 2022


Yes No Not Sure

Inclusion Criteria

Written informed consent
Male or female subject aged ≥18 years and legally capable to provide informed consent
Functioning or non-functioning gastroenteropancreatic (GEP)-neuroendocrine tumor (NET) or unknown primary-NET
Well differentiated tumor
Grade (G) 1, G2 according to the 2017 World Health Organization (WHO) criteria
Subject already treated with Lanreotide Autogel® for the period up to 5 months, according to local standard of care, prior to documentation into this study
Use of Lanreotide autogel® monotherapy by local label (SmPC)
Concomitant locoregional therapy such as surgery, RFA or TAE is allowed

Exclusion Criteria

Parallel participation in an interventional study
Lanreotide treatment for more than 5 months prior inclusion into the study
Prior anti-proliferative medication with somatostatin analogue (e.g. Octreotide LAR)
Concomitant anti-proliferative systemic medication/therapies for GEP-NET are not allowed
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note